$华东医药(SZ000963)$Both Sinclair and Cocoon have bounced back strongly from 2020, with Q1 2021 sales beating expectations at both companies. For Sinclair, the Cocoon acquisition comes during a particularly exciting year, following the launch of Lanluma® (PLLA collagen stimulator) in February, the impending launch of HA filler MaiLi® (with OxiFree® technology), the expected launch of Ellansé® in China in Q3 and the anticipated Q4 launch of Perfectha® with lidocaine.